Recombinant Vector Sustains BMP-7 for Renal Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute and chronic renal failure in mammals are inadequate, with high mortality rates and no effective methods to prevent or reverse kidney structural alterations, and the short half-life of Bone Morphogenetic Protein-7 (BMP-7) requires frequent and costly injections, making it impractical for veterinary medicine.
Innovation Solution
A recombinant plasmid vector is developed for intramuscular delivery, encoding a codon-optimized BMP-7 polypeptide linked to a promoter, allowing for sustained expression and production of BMP-7 in mammals to prevent or treat renal failure, reducing mortality and morbidity by maintaining therapeutic plasma concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant BMP-7 protein is administered by injection, then therapeutic effect is achieved, but frequent injections are required due to short half-life
Solution Approach 1:
The BMP-7 gene is introduced into the subject's cells in advance through viral vector delivery, enabling the cells to produce BMP-7 protein continuously. This preliminary genetic modification eliminates the need for repeated protein injections by establishing endogenous production capability before the therapeutic effect is needed.
Solution Approach 2:
The subject's own cells are engineered to serve as factories for producing BMP-7 protein. Once the gene is delivered, the subject's cellular machinery automatically synthesizes the therapeutic protein, making the system self-sustaining without requiring external administration of the protein.
2Reliability
If recombinant BMP-7 protein is administered by frequent injections, then therapeutic plasma concentrations are maintained, but treatment cost increases
Solution Approach 1:
The subject's own cells are engineered to serve as factories for producing BMP-7 protein. Once the gene is delivered, the subject's cellular machinery automatically synthesizes the therapeutic protein, making the system self-sustaining without requiring external administration of the protein.
3Duration of action of moving object
If BMP-7 gene is delivered to achieve sustained expression, then injection frequency is reduced, but delivery method complexity increases
Solution Approach 1:
A viral vector serves as an intermediary carrier to deliver the BMP-7 gene into the subject's cells. The viral vector naturally infects cells and delivers genetic material, providing an efficient delivery mechanism that bypasses the complexity of direct gene injection or other non-viral delivery methods.
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of both acute and chronic renal failure in mammals, advantageously in dogs and cats, by administration of the recombinant vectors and pharmaceutical compositions of the invention.